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Antidepressant use and risk of adverse
outcomes in people aged 20–64 years:
cohort study using a primary care database
Carol Coupland1* , Trevor Hill1, Richard Morriss2, Michael Moore3, Antony Arthur4 and Julia Hippisley-Cox1
Abstract
Background: Antidepressants are one of the most commonly prescribed medications in young and middle-aged
adults, but there is relatively little information on their safety across a range of adverse outcomes in this age group.
This study aimed to assess associations between antidepressant treatment and several adverse outcomes in people
aged 20–64 years diagnosed with depression.
Methods: We conducted a cohort study in 238,963 patients aged 20–64 years registered with practices across the
UK contributing to the QResearch primary care database. Only patients with a first diagnosis of depression were
included. Outcomes were falls, fractures, upper gastrointestinal bleed, road traffic accidents, adverse drug reactions
and all-cause mortality recorded during follow-up. Cox proportional hazards models were used to estimate hazard
ratios associated with antidepressant exposure adjusting for potential confounding variables.
Results: During 5 years of follow-up, 4651 patients had experienced a fall, 4796 had fractures, 1066 had upper
gastrointestinal bleeds, 3690 had road traffic accidents, 1058 had experienced adverse drug reactions, and 3181 patients
died. Fracture rates were significantly increased for selective serotonin reuptake inhibitors (adjusted hazard ratio 1.30, 95%
CI 1.21–1.39) and other antidepressants (1.28, 1.11–1.48) compared with periods when antidepressants were not used. All
antidepressant drug classes were associated with significantly increased rates of falls. Rates of adverse drug reactions were
significantly higher for tricyclic and related antidepressants (1.54, 1.25–1.88) and other antidepressants (1.61, 1.22–2.12)
compared with selective serotonin reuptake inhibitors. Trazodone was associated with a significantly increased risk of
upper gastrointestinal bleed. All-cause mortality rates were significantly higher for tricyclic and related
antidepressants (1.39, 1.22–1.59) and other antidepressants (1.26, 1.08–1.47) than for selective serotonin reuptake
inhibitors over 5 years but not 1 year, and were significantly reduced after 85 or more days of treatment with
selective serotonin reuptake inhibitors. Mirtazapine was associated with significantly increased mortality rates over
1 and 5 years of follow-up.
Conclusions: Selective serotonin reuptake inhibitors had higher rates of fracture than tricyclic and related
antidepressants but lower mortality and adverse drug reaction rates than the other antidepressant drug classes.
The association between mirtazapine and increased mortality merits further investigation. These risks should be
carefully considered and balanced against potential benefits for individual patients when the decision to
prescribe an antidepressant is made.
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Background
Depression is a serious condition, common in adults of all
ages worldwide [1, 2]. It is frequently treated with anti-
depressant drugs, with many countries reporting substantial
increases in the prescribing rates of these drugs in recent
decades [3–5]. Reports from the US, Canada and UK have
shown that antidepressants are one of the most commonly
prescribed types of medication in young and middle-aged
adults [6–9], taken by 7% of adults aged 18–39 years and
by 14% of adults aged 40–59 in the US [9]. Several different
types of antidepressant drug are available, with broadly
equal efficacy, although there is ongoing debate over their
effectiveness compared to placebo [10–12]. Therefore, the
choice of an antidepressant largely depends on the consid-
eration of potential adverse effects. Guidelines recommend
that selective serotonin reuptake inhibitors should generally
be considered as the first-line treatment for depression
[13].
Despite the widespread use of antidepressants, there is
relatively little information on their safety across a range
of serious adverse outcomes in young and middle-aged
adults. Adverse effects have been evaluated in rando-
mised controlled trials, but these trials are usually in
select groups and are relatively small and short term,
therefore lacking the power to detect rare but serious
adverse effects. Observational studies have shown associ-
ations between the use of selective serotonin reuptake
inhibitors and increased risks of fractures and falls [14, 15],
but these studies have either been carried out only in older
people or have been dominated by outcomes occurring in
older people where event rates are higher. There is some
indication that antidepressants may impair the ability to
drive in older people, but the evidence in younger drivers is
equivocal [16]. Similarly studies have found increased risks
of gastrointestinal bleeds [17], adverse drug reactions [18]
and all-cause mortality [19] associated with antidepressant
use, but there is a lack of evidence in young and middle-
aged adults, where patterns of risk may differ compared with
older people due to greater levels of comorbidity, interac-
tions with other prescribed medications, and increased sus-
ceptibility to adverse effects in older populations [20, 21].
Given the lack of evidence regarding antidepressant safety
in a younger population despite the large numbers of pre-
scriptions issued to this group for increasingly long dura-
tions, we performed a large cohort study in people aged
20–64 years in order to investigate the associations between
different antidepressant drugs and the risks of several
potential adverse outcomes. We aimed to provide a com-
prehensive assessment of risks by drug class, and for the
most commonly prescribed individual antidepressant drugs.
Methods
The cohort study was designed to assess associations
between antidepressant treatment and several different
adverse outcomes, including falls, fractures, upper
gastrointestinal bleed, road traffic accident, adverse drug
reaction, and all-cause mortality. Findings for suicide,
self-harm, epilepsy and cardiovascular outcomes have
been previously reported [22–24]. Full details of the
study design and methods can be found in the study
protocol [25].
Study cohort
A large primary care database (QResearch, version 34)
was used to select the study cohort. At the time of the
study the QResearch database included health records of
over 12 million patients from more than 600 general
practices across the United Kingdom which record data
using the Egton Medical Information Systems (EMIS)
medical records computer system. The information re-
corded includes patient characteristics, clinical diagno-
ses, symptoms and prescribed medications.
The study cohort included patients aged 20–64 years
with a first recorded diagnosis of depression between
January 1, 2000, until July 31, 2011. Diagnostic Read codes,
which are the standard clinical codes used in general prac-
tice in the United Kingdom, were used to identify patients
with a diagnosis of depression, using codes employed in
previous studies [26–28]. Patients were only eligible for
inclusion if their diagnosis of depression occurred at least
12 months after their registration with a study practice and
the installation date of their practice’s EMIS computer
system to ensure it was a new diagnosis and not a retro-
spective recording of a previous diagnosis.
Patients were excluded if they had a previous recorded
diagnosis of depression, or if they had received prescrip-
tions for an antidepressant either before the study start
date (January 1, 2000), before their registration date,
before the age of 20, or more than 36 months before
their first recorded diagnosis of depression. We excluded
patients with a previous diagnosis of depression or pre-
scriptions for antidepressants more than 36 months
prior to diagnosis so that antidepressant prescribing
during follow-up would not be influenced by any prior
experiences or preferences that would be difficult to
account for in the analyses. Where patients were pre-
scribed antidepressants within the 36 months before
their recorded diagnosis of depression we assumed that
these were being prescribed for depression. Patients
were also excluded if they were temporary residents due
to lack of follow-up data or if they had a diagnosis of
schizophrenia, bipolar disorder or another type of psychosis,
or had been prescribed lithium or antimanic drugs to reduce
indication bias.
Each patient’s study entry date was defined as the date
of the first recorded diagnosis of depression, or the date
of the first prescription for an antidepressant if that was
earlier. Patients were then followed up until the earliest
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date of leaving the practice, death or end of the follow-
up period (August 1, 2012).
Outcomes
The outcomes for these analyses were falls, fractures
(including vertebral, rib, pelvis, upper limb, lower limb,
distal radius, hip and skull fractures), upper gastrointes-
tinal bleed, road traffic accidents, adverse drug reactions
and all-cause mortality. Patients with these outcomes
were identified if they were recorded either on the pa-
tients’ general practice record using the relevant Read
codes or on their linked Office of National Statistics
cause of death record using International Classification
of Diseases diagnostic codes, employing codes similar to
those used in previous studies [29–31]. The adverse drug
reactions outcome included specific codes for adverse
reactions to antidepressants, codes for adverse drug
reactions where the drug was not specified and codes for
bullous eruption. Patients with a previous diagnosis of
an outcome were excluded from the analysis of the
respective outcome.
Antidepressant poisoning and sudden death were two
further pre-specified outcomes [25], but numbers of pa-
tients with these outcomes recorded were too small for
further analysis.
Exposures
Information was extracted from all prescriptions for
antidepressants issued during follow-up. We calculated
the duration of each prescription in days by dividing the
number of tablets prescribed by the number of tablets to
be taken each day. If the information on tablets per day
was missing or not sufficiently detailed (< 5% of total pre-
scriptions) we estimated the duration of the prescription
based on the number of tablets prescribed, as in our previ-
ous study [29]. Antidepressant drugs were grouped
according to the four main classes in the British National
Formulary: tricyclic and related antidepressants, selective
serotonin reuptake inhibitors, monoamine oxidase inhibi-
tors and other antidepressants. If different antidepressant
drugs were prescribed on the same date these were classi-
fied as combined prescriptions. Patients were classified as
continually exposed to an antidepressant during periods
where there were no gaps of more than 90 days between
the end of one prescription and the start of the next.
Patients were also classified as exposed for the first 90
days after the estimated date of stopping an antidepressant
in order to account for any delays in starting the prescrip-
tion or accumulation of tablets as well as to attribute the
outcomes occurring during withdrawal periods to the
antidepressant.
The daily dose of each prescription was calculated by
multiplying the number of tablets to be taken each day
by the dose of each tablet, and then converted to a
defined daily dose using values assigned by the World
Health Organization’s Collaborating Centre for Drug
Statistics Methodology (www.whocc.no/atc_ddd_index).
The 11 most commonly prescribed individual anti-
depressant drugs were also assessed separately, as in our
previous study [26].
Confounding variables
Confounders were variables considered to be potential
risk factors for the outcomes or associated with the like-
lihood of receiving a particular antidepressant treatment,
based on our previous study of antidepressants in people
aged 65 or over [26]. These were age at study entry; sex;
year of diagnosis of depression; severity of index diagno-
sis of depression (categorised as mild, moderate or
severe, using codes published by Martinez et al. [27] and
some further classification of additional codes included
in this study by a member of the study team); deprivation
(Townsend deprivation score corresponding to the
patients postcode, in fifths); smoking status (non-smoker,
ex-smoker, light smoker: 1–9 cigarettes/day, moderate
smoker: 10–19 cigarettes/day, heavy smoker: ≥ 20
cigarettes/day, not recorded); alcohol intake (none, trivial:
< 1 unit/day, light: 1–2 units/day, medium: 3–6 units/day,
heavy: 7–9 units/day, very heavy: > 9 units/day, not
recorded); ethnic group (categorised as either white/not
recorded or non-white (Indian, Pakistani, Bangladeshi,
other Asian, black African, black Caribbean, Chinese,
other including mixed)); comorbidities at baseline (bin-
ary variables for each of coronary heart disease, stroke/
transient ischaemic attack, diabetes, hypertension, can-
cer, epilepsy/seizures, hypothyroidism, osteoarthritis,
rheumatoid arthritis, asthma/chronic obstructive air-
ways disease, osteoporosis, liver disease, renal disease,
obsessive-compulsive disorder); and use of other drugs
at baseline (binary variables for each of antihypertensive
drugs, aspirin, statins, anticoagulants, non-steroidal
anti-inflammatory drugs, anticonvulsants, hypnotics/
anxiolytics, anti-psychotics, bisphosphonates, oral con-
traceptives, hormone replacement therapy). In addition,
a record of falls at baseline was included as a confound-
ing variable for the fracture outcome.
Statistical analysis
Cox’s proportional hazards model was used to estimate
associations between each of the outcomes and anti-
depressant drug exposure, using robust standard errors
to allow for clustering of patients within practices and
excluding patients from the analysis if they had the out-
come recorded at baseline. The main analyses were
based on the first 5 years of follow-up after study entry.
We selected 5 years of follow-up for the main analyses
as this includes periods of long-term treatment and
allows more events to accrue to increase the power of
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the study compared with a shorter period. Patients pre-
scribed monoamine oxidase inhibitors at any time were
excluded from the analyses due to small numbers.
The analysis calculated unadjusted and adjusted
hazard ratios (HRs) by antidepressant class treated as a
time-varying exposure to allow for patients starting and
stopping and also changing between treatments during
follow-up. The reference category for these analyses
was no current use of antidepressant treatment. This
category included both unexposed time in patients
treated with antidepressants at other time points during
follow-up, as well as unexposed time from the group
of patients who did not receive any prescriptions for anti-
depressants during follow-up. In an additional analysis
we used treatment with selective serotonin reuptake in-
hibitors as the reference category. We used Wald’s sig-
nificance tests to identify significant differences between
the antidepressant classes.
Analyses were also performed for antidepressant dose
with separate dose categories within each class (≤ 0.5, > 0.5
and ≤ 1.0, and > 1.0 defined daily doses). We carried out
tests for trend for each class using dose as a continuous
variable. Analyses were performed for time-varying expo-
sures of time since starting treatment (categorised as no
use, 1–28 days, 29–84 days, 85 or more days) and since
stopping (1–28 days, 29–84 days and 85–182 days after
stopping treatment) within each antidepressant class. The
11 most commonly prescribed antidepressants were also
analysed separately, first using periods of time with no anti-
depressant treatment as the reference category then using
citalopram (the most commonly prescribed antidepressant)
as the reference category, and we used Wald’s significance
tests to identify significant differences between these 11
drugs. We tested for interactions between antidepressant
class and age and also for the upper gastrointestinal bleed
outcome we tested for interactions between antidepressant
class and non-steroidal anti-inflammatory drugs and
aspirin. We assessed the proportional hazards assumption
using log minus log plots.
Three sensitivity analyses were performed [22]. In the
first, we restricted the analyses to the first year of
follow-up, since baseline characteristics are less likely to
change within this period, and fewer switches occur
between different antidepressant drugs, so the results
are less susceptible to residual confounding. In the sec-
ond sensitivity analysis, the entire follow-up period was
included to increase power and encompass long dura-
tions of antidepressant use. The third sensitivity analysis
used 5 years of follow-up and excluded patients who had
not received any antidepressant prescriptions during
follow-up. We carried out this third analysis because
patients who were untreated during follow-up might
differ systematically from treated patients (such as
having a dislike of taking tablets, a preference for non-
drug treatments or less severe depression), and these dif-
ferences could distort comparisons with the untreated
reference category.
We calculated absolute risks of the outcomes over 1
year based on the method described by Altman et al.
[32], accounting for the confounding variables by using
the adjusted hazard ratios (aHRs) from the analyses
based on 1 year of follow-up.
We used all eligible patients in the database to maxi-
mise power. We used a P value of less than 0.01 (two-
tailed) to determine statistical significance. Analyses
were carried out using Stata (v12.1).
Results
The initial cohort included 327,235 patients with a first
diagnosis of depression made during the study period
and between the ages of 20 and 64 years. A total of
88,272 (27.0%) patients were excluded because they had
been prescribed an antidepressant either before the
study entry date, before age 20 or more than 36 months
before their date of diagnosis of depression, or had
schizophrenia, bipolar disorder or other psychoses, or
had been prescribed lithium or antimanic drugs. This
left 238,963 eligible patients in the final study cohort
(Fig. 1).
The total length of follow-up was 1,307,326 person-
years, with a median of 5.2 years per person. Character-
istics of the study cohort at baseline are shown in
Table 1. The cohort included 146,028 (61%) women and
the mean age was 39.5 (SD 11.1) years.
Antidepressant treatment during follow-up
The majority of patients in the cohort (209,476, 87.7%)
were treated with antidepressants during follow-up. The
median duration of treatment was 221 days (interquar-
tile range 79–590 days), with 36.6% of treated patients
having 1 or more years of treatment and 5.5% having 5
or more years of treatment. Selective serotonin reuptake
inhibitors were the most frequently prescribed antidepres-
sant class (189,968 patients had 2,379,668 prescriptions),
followed by tricyclic and related antidepressants (61,901
patients had 533,798 prescriptions), other antidepressants
(33,631 patients had 422,079 prescriptions), and
monoamine oxidase inhibitors (156 patients had a total of
1791 prescriptions). There were 83,784 combined pre-
scriptions where two or more different antidepressant
drugs were prescribed on the same day.
The three most commonly prescribed antidepressants
were citalopram (1,023,255 prescriptions; 31.5%), fluox-
etine (778,285; 23.9%) and amitriptyline (236,416; 7.3%),
out of a total of 3,252,633 prescriptions (with combined
prescriptions counting as single prescriptions). Numbers
of prescriptions overall and by prescribed daily dose
category for the 11 most commonly prescribed
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antidepressants are shown in Additional file 1: Table S1.
Prescribed doses tended to be lowest for tricyclic and re-
lated antidepressants, with the exception of lofepramine,
which had the highest prescribed doses.
Incidence rates
At baseline, 4321 patients had a previous fall recorded,
23,746 had a prior fracture recorded, 1600 had a prior
upper gastrointestinal bleed, 9372 a previous road traffic
accident, and 1114 a previous adverse drug reaction.
These patients were excluded from analyses of each
respective outcome, along with the 156 patients
prescribed monoamine oxidase inhibitors.
During the first 5 years of follow-up, 4651 patients
experienced one or more falls (incidence rate of 529 per
100,000 person-years), 4796 had fractures (596 per
100,000), 1066 had an upper gastrointestinal bleed (119
per 100,000), 3690 had a road traffic accident (428 per
100,000), and 1058 experienced an adverse drug reaction
(118 per 100,000); further, there were 3181 deaths from
all causes (351 per 100,000). In addition, 74 patients had
antidepressant poisoning recorded (8 per 100,000), and
there were 16 sudden deaths (2 per 100,000).
Results of analyses for falls
Table 2 shows hazard ratios for each antidepressant class
compared with periods of time when these drugs were
not being used over the 5 years of follow-up. There were
significantly increased rates of falls in all antidepressant
classes compared with untreated periods of time. Table 3
presents HRs with selective serotonin reuptake inhibitor
treatment as the reference category and shows that, in a
direct comparison of fall rates between the antidepres-
sant classes, there were no significant differences overall
(P = 0.59). There were significant trends in fall rates by
dose in each of the drug classes (Table 4).
Eight of the 11 most commonly prescribed antidepres-
sants were associated with significantly increased fall
rates (at P < 0.01) when compared with non-use over 5
years of follow-up (Fig. 2); for dosulepin, the association
was significant at P = 0.013. Table 5 presents HRs with
citalopram as the reference category and shows that
Fig. 1 Flow chart for selection of patients included in study cohort
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there were no overall significant differences between the
rates for these 11 drugs.
In the analysis restricted to the first year of follow-up,
aHRs for the antidepressant drug classes compared with
untreated periods were smaller than in the analysis with
5 years of follow-up (Table 6).
Results of analyses for fracture
Over 5 years of follow-up, the fracture rate was significantly
increased for selective serotonin reuptake inhibitors (aHR
1.30, 95% CI 1.21–1.39) and other antidepressants (1.28,
95% CI 1.11–1.48), but not tricyclic and related antidepres-
sants (0.92, 95% CI 0.80–1.06) when compared with periods
of time when antidepressants were not being used (Table 2).
There was a significantly lower fracture rate for tricyclic
and related antidepressants when directly compared with
selective serotonin reuptake inhibitors (aHR 0.71, 95% CI
0.61–0.82) with significant differences (P < 0.001) between
the antidepressant drug classes overall (Table 3). Fracture
rates increased significantly with dose only for selective
serotonin reuptake inhibitors (Table 4).
There were significantly increased fracture rates for citalo-
pram, escitalopram, fluoxetine, sertraline and venlafaxine
when compared with no use of antidepressants over 5 years
of follow-up (Fig. 2). In a direct comparison with citalopram
as the reference category, fracture rates were significantly
Table 1 Characteristics of the study cohort (n = 238,963) at baseline
Characteristic n %a
Sex
Male 92,935 (38.9)
Female 146,028 (61.1)
Mean age (SD) 39.5 (11.1)
Ethnic group recorded 136,624 (57.2)
Ethnic group:
White/not recorded 227,451 (95.2)
Non-white 11,512 (4.8)
Depression severity (index diagnosis):
Mild 171,208 (71.7)
Moderate 59,140 (24.8)
Severe 8615 (3.6)
Smoking statusb:
Recorded 233,290 (97.6)
Non smoker 110,849 (47.5)
Ex-smoker 35,132 (15.1)
Current light smoker 24,104 (10.3)
Current moderate smoker 40,546 (17.4)
Current heavy smoker 22,659 (9.7)
Alcohol consumptionb:
Recorded 203,189 (85.0)
Non drinker 55,253 (27.2)
Trivial (less than 1 unit per day) 77,579 (38.2)
Light (1–2 units per day) 51,310 (25.3)
Moderate (3–6 units per day) 14,482 (7.1)
Heavy (7–9 units per day) 2174 (1.1)
Very heavy (over 9 units per day) 2391 (1.2)
Townsend deprivation score in fifthsb:
Recorded 230,762 (96.6)
1 (Least deprived) 45,021 (19.5)
2 46,207 (20.0)
3 48,293 (20.9)
4 47,063 (20.4)
5 (Most deprived) 44,178 (19.1)
Comorbidities at baseline:
Any cancer 3810 (1.6)
Asthma/chronic obstructive airways disease 31,816 (13.3)
Coronary heart disease 4109 (1.7)
Diabetes 7371 (3.1)
Hypertension 17,217 (7.2)
Stroke/transient ischaemic attack 1741 (0.7)
Epilepsy/seizures 3325 (1.4)
Previous falls 4321 (1.8)
Hypothyroidism 5267 (2.2)
Table 1 Characteristics of the study cohort (n = 238,963) at baseline
(Continued)
Characteristic n %a
Obsessive-compulsive disorder 494 (0.2)
Osteoarthritis 7228 (3.0)
Osteoporosis 867 (0.4)
Liver disease 698 (0.3)
Renal disease 549 (0.2)
Rheumatoid arthritis 1301 (0.5)
Medications at baseline:
Anticonvulsants 2672 (1.1)
Antihypertensive drugs 25,344 (10.6)
Antipsychotics 836 (0.4)
Anticoagulants 1073 (0.5)
Aspirin 7159 (3.0)
Bisphosphonates 854 (0.4)
Hypnotics/anxiolytics 11,354 (4.8)
Non-steroidal anti-inflammatory drugs 12,725 (5.3)
Statins 10,823 (4.5)
Oral contraceptivesc 27,396 (18.8)
Hormone replacement therapyc 7207 (4.9)
aValues are numbers (column percentages) unless stated otherwise
bPercentages for smoking status, alcohol and deprivation are out of total with
recorded values
cPercentage is for females only
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Table 2 Unadjusted and adjusted hazard ratios for six adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic
accident, adverse drug reaction, and all-cause mortality) by antidepressant class compared with periods of non-use of antidepres-
sants over 5 years follow-up
Unadjusted analysis Adjusted analysisb
Antidepressant class No of eventsa Person-yearsa Hazard ratio 95% CI Hazard ratio 95% CI P
Falls
No current use 2493 558,933 1.00 1.00
TCAs 298 40,260 1.79 (1.58–2.04) 1.36 (1.19–1.54) < 0.001
SSRIs 1494 221,813 1.62 (1.52–1.73) 1.48 (1.39–1.59) < 0.001
Other antidepressants 189 27,678 1.64 (1.42–1.89) 1.43 (1.23–1.66) < 0.001
Combined antidepressants 37 4121 2.03 (1.48–2.78) 1.61 (1.16–2.22) 0.004
Fracture
No current use 2759 510,172 1.00 1.00
TCAs 205 37,309 1.04 (0.90–1.20) 0.92 (0.80–1.06) 0.26
SSRIs 1466 204,592 1.35 (1.26–1.44) 1.30 (1.21–1.39) < 0.001
Other antidepressants 195 25,164 1.43 (1.24–1.65) 1.28 (1.11–1.48) 0.001
Combined antidepressants 29 3759 1.39 (0.94–2.06) 1.22 (0.82–1.81) 0.32
Upper GI bleed
No current use 588 570,654 1.00 1.00
TCAs 79 41,295 1.83 (1.45–2.29) 1.43 (1.13–1.81) 0.003
SSRIs 300 226,336 1.21 (1.05–1.39) 1.16 (1.00–1.33) 0.045
Other antidepressants 50 28,102 1.74 (1.31–2.31) 1.35 (1.00–1.82) 0.050
Combined antidepressants 12 4245 2.65 (1.49–4.69) 2.13 (1.19–3.79) 0.010
Road traffic accident
No current use 2343 546,915 1.00 1.00
TCAs 154 39,929 0.87 (0.72–1.05) 0.97 (0.80–1.17) 0.72
SSRIs 929 218,137 0.97 (0.89–1.05) 1.03 (0.95–1.12) 0.47
Other antidepressants 120 27,221 1.01 (0.84–1.22) 1.08 (0.90–1.30) 0.41
Combined antidepressants 18 4063 1.00 (0.64–1.56) 1.12 (0.71–1.76) 0.62
Adverse drug reaction
No current use 432 571,401 1.00 1.00
TCAs 122 41,380 3.11 (2.50–3.87) 2.69 (2.15–3.37) < 0.001
SSRIs 396 226,577 1.88 (1.62–2.19) 1.75 (1.50–2.04) < 0.001
Other antidepressants 70 28,197 3.03 (2.29–4.01) 2.81 (2.11–3.75) < 0.001
Combined antidepressants 11 4257 3.29 (1.81–5.97) 2.92 (1.60–5.35) 0.001
All-cause mortality
No current use 1541 575,623 1.00 1.00
TCAs 326 41,807 2.89 (2.54–3.29) 1.92 (1.68–2.19) < 0.001
SSRIs 990 228,233 1.63 (1.50–1.78) 1.38 (1.26–1.51) < 0.001
Other antidepressants 196 28,487 2.61 (2.24–3.03) 1.74 (1.48–2.06) < 0.001
Combined antidepressants 41 4299 3.62 (2.69–4.88) 2.19 (1.60–3.00) < 0.001
aBased on numbers in adjusted analysis (patients with missing values for confounding variables were excluded from the adjusted analyses – during 5 years
follow-up, 141 of these patients had falls, 142 had fractures, 37 had upper gastrointestinal bleeds, 126 had road traffic accidents, 27 had adverse drug reactions
and 87 died)
bAdjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group (white/not recorded or
non-white), coronary heart disease, diabetes, hypertension, cancer, epilepsy/seizures, hypothyroidism, osteoarthritis, asthma/chronic obstructive airways disease,
stroke/TIA, rheumatoid arthritis, osteoporosis, liver disease, renal disease, obsessive-compulsive disorder, statins, NSAIDS, aspirin, antihypertensive drugs, anticon-
vulsants, hypnotics/anxiolytics, oral contraceptives, hormone replacement therapy, antipsychotics, bisphosphonates, anticoagulants; fracture outcome also adjusted
for falls
GI gastrointestinal, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic and related antidepressants
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Table 3 Unadjusted and adjusted hazard ratios for six adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic
accident, adverse drug reaction, and all-cause mortality) by antidepressant class compared with selective serotonin reuptake inhibi-
tors over 5 years follow-up
Unadjusted analysis Adjusted analysisb
Antidepressant class No of eventsa Person-yearsa Hazard ratio 95% CI Hazard ratio 95% CI P
Falls
SSRIs 1494 221,813 1.00 1.00
TCAs 298 40,260 1.11 (0.97–1.26) 0.91 (0.80–1.05) 0.20
Other antidepressants 189 27,678 1.01 (0.88–1.17) 0.96 (0.83–1.12) 0.62
Combined antidepressants 37 4121 1.25 (0.91–1.72) 1.08 (0.78–1.50) 0.63
No current use 2493 558,933 0.62 (0.58–0.66) 0.67 (0.63–0.72) < 0.001
Comparison between groupsc 0.59
Fracture
SSRIs 1466 204,592 1.00 1.00
TCAs 205 37,309 0.77 (0.67–0.89) 0.71 (0.61–0.82) < 0.001
Other antidepressants 195 25,164 1.06 (0.91–1.24) 0.99 (0.85–1.15) 0.85
Combined antidepressants 29 3759 1.03 (0.69–1.54) 0.94 (0.63–1.40) 0.77
No current use 2759 510,172 0.74 (0.69–0.79) 0.77 (0.72–0.83) < 0.001
Comparison between groupsc < 0.001
Upper GI bleed
SSRIs 300 226,336 1.00 1.00
TCAs 79 41,295 1.51 (1.20–1.91) 1.24 (0.97–1.57) 0.08
Other antidepressants 50 28,102 1.44 (1.08–1.93) 1.17 (0.86–1.57) 0.32
Combined antidepressants 12 4245 2.19 (1.23–3.92) 1.84 (1.03–3.30) 0.041
No current use 588 570,654 0.83 (0.72–0.95) 0.86 (0.75–1.00) 0.045
Comparison between groupsc 0.07
Road traffic accident
SSRIs 929 218,137 1.00 1.00
TCAs 154 39,929 0.90 (0.74–1.09) 0.94 (0.77–1.14) 0.51
Other antidepressants 120 27,221 1.05 (0.86–1.27) 1.05 (0.87–1.27) 0.63
Combined antidepressants 18 4063 1.03 (0.66–1.62) 1.09 (0.69–1.72) 0.72
No current use 2343 546,915 1.03 (0.95–1.12) 0.97 (0.89–1.05) 0.47
Comparison between groupsc 0.84
Adverse drug reaction
SSRIs 396 226,577 1.00 1.00
TCAs 122 41,380 1.65 (1.35–2.01) 1.54 (1.25–1.88) < 0.001
Other antidepressants 70 28,197 1.61 (1.23–2.11) 1.61 (1.22–2.12) 0.001
Combined antidepressants 11 4257 1.75 (0.96–3.16) 1.67 (0.92–3.04) 0.09
No current use 432 571,401 0.53 (0.46–0.62) 0.57 (0.49–0.67) < 0.001
Comparison between groupsc < 0.001
All-cause mortality
SSRIs 990 228,233 1.00 1.00
TCAs 326 41,807 1.77 (1.55–2.01) 1.39 (1.22–1.59) < 0.001
Other antidepressants 196 28,487 1.59 (1.38–1.84) 1.26 (1.08–1.47) 0.003
Combined antidepressants 41 4299 2.22 (1.64–2.99) 1.58 (1.16–2.17) 0.004
No current use 1541 575,623 0.61 (0.56–0.67) 0.72 (0.66–0.79) < 0.001
Comparison between groupsc < 0.001
aBased on numbers in adjusted analysis
bAdjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group (white/not recorded or non-white),
coronary heart disease, diabetes, hypertension, cancer, epilepsy/seizures, hypothyroidism, osteoarthritis, asthma/chronic obstructive airways disease, stroke/TIA, rheumatoid
arthritis, osteoporosis, liver disease, renal disease, obsessive-compulsive disorder, statins, NSAIDS, aspirin, antihypertensive drugs, anticonvulsants, hypnotics/anxiolytics, oral
contraceptives, hormone replacement therapy, antipsychotics, bisphosphonates, anticoagulants; fracture outcome also adjusted for falls
cComparison between the different drug classes including combined antidepressants but not including no current use
GI gastrointestinal, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic and related antidepressants
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Table 4 Unadjusted and adjusted hazard ratios for 6 adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic
accident, adverse drug reaction, and all-cause mortality) by antidepressant dose compared with periods of non-use of antidepres-
sants over 5 years follow-up
Unadjusted analysis Adjusted analysisc
Antidepressant class and dose categoriesa No of eventsb Person-yearsb Hazard ratio 95% CI Hazard ratio 95% CI P
Falls
No current use 2493 558,933 1.00 1.00
TCAs:
≤ 0.5 DDD 164 22,997 1.76 (1.49–2.08) 1.27 (1.07–1.50) 0.007
> 0.5 DDD/≤ 1.0 DDD 64 8191 1.88 (1.50–2.37) 1.43 (1.13–1.80) 0.003
> 1.0 DDD 46 5165 2.03 (1.50–2.75) 1.75 (1.30–2.36) < 0.001
Test for trendd 0.009
SSRIs:
≤ 0.5 DDD 91 15,835 1.35 (1.09–1.67) 1.19 (0.96–1.47) 0.12
> 0.5 DDD/≤ 1.0 DDD 1018 155,545 1.61 (1.49–1.73) 1.45 (1.35–1.57) < 0.001
> 1.0 DDD 343 41,804 1.85 (1.65–2.08) 1.76 (1.56–1.98) < 0.001
Test for trendd 0.001
Others:
≤ 0.5 DDD 20 3967 1.14 (0.74–1.75) 1.00 (0.65–1.53) 1.00
> 0.5 DDD/≤ 1.0 DDD 86 13,046 1.62 (1.32–2.00) 1.38 (1.12–1.72) 0.003
> 1.0 DDD 68 8274 1.90 (1.51–2.39) 1.75 (1.38–2.21) < 0.001
Test for trendd 0.003
Fracture
No current use 2759 510,172 1.00 1.00
TCAs:
≤ 0.5 DDD 112 21,414 0.97 (0.81–1.16) 0.87 (0.72–1.05) 0.16
> 0.5 DDD/≤ 1.0 DDD 47 7535 1.18 (0.89–1.56) 1.01 (0.76–1.36) 0.92
> 1.0 DDD 27 4739 1.09 (0.76–1.58) 0.94 (0.65–1.38) 0.77
Test for trendd 0.55
SSRIs:
≤ 0.5 DDD 97 14,710 1.26 (1.03–1.54) 1.21 (0.98–1.49) 0.07
> 0.5 DDD/≤ 1.0 DDD 988 143,425 1.29 (1.19–1.40) 1.24 (1.15–1.35) < 0.001
> 1.0 DDD 336 38,450 1.61 (1.44–1.80) 1.52 (1.35–1.70) < 0.001
Test for trendd 0.004
Others:
≤ 0.5 DDD 25 3655 1.28 (0.86–1.91) 1.12 (0.74–1.69) 0.58
> 0.5 DDD/≤ 1.0 DDD 90 11,805 1.39 (1.12–1.72) 1.25 (1.01–1.56) 0.04
> 1.0 DDD 68 7525 1.66 (1.31–2.11) 1.48 (1.16–1.89) 0.001
Test for trendd 0.08
Upper GI bleed
No current use 588 570,654 1.00 1.00
TCAs:
≤ 0.5 DDD 48 23,604 1.96 (1.45–2.64) 1.57 (1.15–2.14) 0.004
> 0.5 DDD/≤ 1.0 DDD 15 8387 1.61 (0.94–2.74) 1.26 (0.74–2.14) 0.40
> 1.0 DDD 8 5307 1.50 (0.74–3.03) 1.06 (0.50–2.27) 0.88
Test for trendd 0.23
SSRIs:
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Table 4 Unadjusted and adjusted hazard ratios for 6 adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic
accident, adverse drug reaction, and all-cause mortality) by antidepressant dose compared with periods of non-use of antidepres-
sants over 5 years follow-up (Continued)
Unadjusted analysis Adjusted analysisc
Antidepressant class and dose categoriesa No of eventsb Person-yearsb Hazard ratio 95% CI Hazard ratio 95% CI P
≤ 0.5 DDD 19 16,165 1.11 (0.72–1.71) 1.20 (0.77–1.86) 0.43
> 0.5 DDD/≤ 1.0 DDD 218 158,584 1.22 (1.04–1.44) 1.20 (1.01–1.42) 0.03
> 1.0 DDD 55 42,780 1.28 (0.99–1.67) 1.08 (0.82–1.42) 0.58
Test for trendd 0.83
Others:
≤ 0.5 DDD 5 4046 1.12 (0.46–2.70) 1.00 (0.41–2.41) 1.00
> 0.5 DDD/≤ 1.0 DDD 20 13,234 1.56 (0.98–2.47) 1.12 (0.67–1.85) 0.66
> 1.0 DDD 17 8398 2.00 (1.28–3.15) 1.54 (0.97–2.46) 0.07
Test for trendd 0.89
Road traffic accident
No current use 2343 546,915 1.00 1.00
TCAs:
≤ 0.5 DDD 91 22,781 0.91 (0.74–1.13) 1.02 (0.82–1.27) 0.85
> 0.5 DDD/≤ 1.0 DDD 28 8161 0.76 (0.50–1.17) 0.84 (0.55–1.30) 0.44
> 1.0 DDD 25 5145 1.06 (0.69–1.62) 1.15 (0.75–1.76) 0.52
Test for trendd 0.67
SSRIs:
≤ 0.5 DDD 57 15,607 0.87 (0.67–1.13) 0.94 (0.72–1.22) 0.62
> 0.5 DDD/≤ 1.0 DDD 659 152,874 0.97 (0.89–1.06) 1.04 (0.95–1.14) 0.39
> 1.0 DDD 176 41,186 0.99 (0.85–1.15) 1.03 (0.87–1.20) 0.76
Test for trendd 0.64
Others:
≤ 0.5 DDD 14 3906 0.91 (0.53–1.55) 0.91 (0.53–1.58) 0.74
> 0.5 DDD/≤ 1.0 DDD 52 12,828 0.90 (0.68–1.19) 0.98 (0.74–1.30) 0.90
> 1.0 DDD 41 8158 1.15 (0.84–1.56) 1.23 (0.90–1.68) 0.20
Test for trendd 0.21
Adverse drug reaction
No current use 432 571,401 1.00 1.00
TCAs:
≤ 0.5 DDD 71 23,632 3.10 (2.40–4.02) 2.59 (1.98–3.38) < 0.001
> 0.5 DDD/≤ 1.0 DDD 18 8425 2.43 (1.47–4.02) 2.12 (1.28–3.51) 0.004
> 1.0 DDD 19 5320 4.03 (2.51–6.49) 3.74 (2.32–6.01) < 0.001
Test for trendd 0.79
SSRIs:
≤ 0.5 DDD 25 16,162 1.65 (1.09–2.49) 1.50 (0.99–2.27) 0.059
> 0.5 DDD/≤ 1.0 DDD 304 158,743 1.97 (1.66–2.33) 1.81 (1.53–2.15) < 0.001
> 1.0 DDD 51 42,866 1.58 (1.19–2.11) 1.46 (1.08–1.97) 0.013
Test for trendd 0.36
Others:
≤ 0.5 DDD 11 4051 3.36 (1.87–6.03) 2.79 (1.51–5.16) 0.001
> 0.5 DDD/≤ 1.0 DDD 28 13,281 2.54 (1.73–3.74) 2.35 (1.58–3.48) < 0.001
> 1.0 DDD 18 8437 2.79 (1.72–4.53) 2.72 (1.68–4.43) < 0.001
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reduced for amitriptyline (aHR 0.68, 95% CI 0.55–0.83) and
dosulepin (aHR 0.67, 95% CI 0.51–0.87) (Table 5), with
some indication of significant differences between the 11
most commonly prescribed antidepressants (P = 0.015).
aHRs for the antidepressant drug classes compared
with untreated periods in two separate age groups
(20–44, 45–64 years) are shown in Additional file 1:
Table S2; there was a significant interaction between drug
class and age (P = 0.01). For the group of other antidepres-
sants there was a significantly increased risk in people aged
20–44 (aHR 1.50, 95% CI 1.25–1.80) but no significant asso-
ciation in people aged 45–64 (aHR 1.04, 95% CI 0.82–1.32).
Selective serotonin reuptake inhibitors were associated with
a significantly increased risk of fracture in both age groups.
aHRs for selective serotonin reuptake inhibitors compared
with untreated periods were similar in men (1.31, 95% CI
1.18–1.45) and women (1.30, 95% CI 1.19–1.42).
Results of analyses for upper gastrointestinal bleed
Rates of upper gastrointestinal bleed over 5 years of follow-
up were significantly increased for tricyclic and related
antidepressants and combined antidepressants compared
with no use of antidepressants (Table 2), although they
were not significantly increased when directly compared
with selective serotonin reuptake inhibitors (Table 3). Fur-
ther, there were no significant differences between the anti-
depressant drug classes overall (P = 0.07) and no significant
trends with dose (Table 4).
Trazodone was associated with a significantly in-
creased rate of upper gastrointestinal bleeds compared
with no use of antidepressants over 5 years of follow-up
(Fig. 2). In a direct comparison with citalopram as the
reference group, the aHR for trazodone was 2.73 (95%
CI 1.44–5.17), and there was also some indication of an in-
creased risk for venlafaxine (aHR 1.53, 95% CI 1.03–2.27),
although there were no significant overall differences be-
tween the 11 most commonly prescribed antidepressants
(P = 0.08) (Table 5).
HRs for selective serotonin reuptake inhibitors, other
antidepressants and combined antidepressants compared
with untreated periods were higher in people aged 20–44
than people aged 45–64 (Additional file 1: Table S2), but
Table 4 Unadjusted and adjusted hazard ratios for 6 adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic
accident, adverse drug reaction, and all-cause mortality) by antidepressant dose compared with periods of non-use of antidepres-
sants over 5 years follow-up (Continued)
Unadjusted analysis Adjusted analysisc
Antidepressant class and dose categoriesa No of eventsb Person-yearsb Hazard ratio 95% CI Hazard ratio 95% CI P
Test for trendd 0.58
All-cause mortality
No current use 1541 575,623 1.00 1.00
TCAs:
≤ 0.5 DDD 180 23,895 2.77 (2.34–3.27) 1.77 (1.49–2.11) < 0.001
> 0.5 DDD/≤ 1.0 DDD 69 8502 2.96 (2.30–3.80) 2.02 (1.55–2.62) < 0.001
> 1.0 DDD 41 5363 2.89 (2.12–3.95) 1.92 (1.37–2.68) < 0.001
Test for trendd 0.48
SSRIs:
≤ 0.5 DDD 81 16,289 1.85 (1.49–2.31) 1.57 (1.25–1.95) < 0.001
> 0.5 DDD/≤ 1.0 DDD 663 159,847 1.56 (1.42–1.73) 1.32 (1.19–1.47) < 0.001
> 1.0 DDD 195 43,226 1.67 (1.43–1.94) 1.40 (1.19–1.65) < 0.001
Test for trendd 0.77
Others:
≤ 0.5 DDD 46 4100 4.15 (3.13–5.52) 2.59 (1.89–3.54) < 0.001
> 0.5 DDD/≤ 1.0 DDD 87 13,404 2.48 (1.99–3.08) 1.61 (1.27–2.03) < 0.001
> 1.0 DDD 47 8529 2.12 (1.60–2.80) 1.48 (1.10–1.99) 0.009
Test for trendd 0.19
aDaily doses could not be evaluated for some prescriptions
bBased on numbers in adjusted analysis
cAdjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group (white/not recorded or
non-white), coronary heart disease, diabetes, hypertension, cancer, epilepsy/seizures, hypothyroidism, osteoarthritis, asthma/chronic obstructive airways disease,
rheumatoid arthritis, osteoporosis, liver disease, renal disease, obsessive-compulsive disorder, statins, NSAIDS, aspirin, antihypertensive drugs, anticonvulsants,
hypnotics/anxiolytics, oral contraceptives, hormone replacement therapy, antipsychotics, bisphosphonates, anticoagulants; fracture outcome also adjusted for falls
dTest for trend uses continuous values of dose
DDD defined daily dose, GI gastrointestinal, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic and related antidepressants
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the interaction between drug class and age was not statis-
tically significant (P = 0.11). There were no significant in-
teractions between antidepressant drug class and use of
either non-steroidal anti-inflammatory drugs or aspirin.
In the analysis restricted to the first year of follow-up,
the aHR for the group of other antidepressants compared
with untreated periods was higher than in the 5-year ana-
lysis (aHR 2.42, 95% CI 1.56–3.76 for 1 year analysis) but
citalopram (SSRI)
escitalopram (SSRI)
fluoxetine (SSRI)
paroxetine (SSRI)
sertraline (SSRI)
amitriptyline (TCA)
dosulepin (TCA)
lofepramine (TCA)
trazodone (TCA)
mirtazapine (Other)
venlafaxine (Other)
all others
Antidepressant
1.49 (1.36, 1.63)
1.51 (1.24, 1.83)
1.48 (1.34, 1.64)
1.56 (1.28, 1.91)
1.38 (1.12, 1.69)
1.46 (1.26, 1.71)
1.35 (1.07, 1.71)
1.18 (0.80, 1.74)
1.46 (0.87, 2.46)
1.44 (1.15, 1.82)
1.37 (1.13, 1.67)
1.24 (0.88, 1.74)
hazard ratio (95% CI)
adjusted
10 .5 1.5 2 2.5
adjusted hazard ratio
hazard ratios compared to no treatment
falls
citalopram (SSRI)
escitalopram (SSRI)
fluoxetine (SSRI)
paroxetine (SSRI)
sertraline (SSRI)
amitriptyline (TCA)
dosulepin (TCA)
lofepramine (TCA)
trazodone (TCA)
mirtazapine (Other)
venlafaxine (Other)
all others
Antidepressant
1.36 (1.24, 1.48)
1.32 (1.07, 1.63)
1.25 (1.13, 1.39)
1.17 (0.96, 1.43)
1.29 (1.08, 1.53)
0.92 (0.75, 1.12)
0.90 (0.69, 1.18)
1.13 (0.79, 1.62)
1.11 (0.68, 1.80)
1.26 (0.99, 1.60)
1.30 (1.06, 1.58)
0.86 (0.58, 1.25)
hazard ratio (95% CI)
adjusted
10 .5 1.5 2
adjusted hazard ratio
hazard ratios compared to no treatment
fracture
citalopram (SSRI)
escitalopram (SSRI)
fluoxetine (SSRI)
paroxetine (SSRI)
sertraline (SSRI)
amitriptyline (TCA)
dosulepin (TCA)
lofepramine (TCA)
trazodone (TCA)
mirtazapine (Other)
venlafaxine (Other)
all others
Antidepressant
1.04 (0.84, 1.29)
1.34 (0.86, 2.09)
1.29 (1.06, 1.58)
1.22 (0.81, 1.82)
0.82 (0.52, 1.30)
1.34 (0.97, 1.86)
1.36 (0.91, 2.05)
1.07 (0.47, 2.42)
2.83 (1.53, 5.24)
1.24 (0.78, 1.96)
1.59 (1.11, 2.29)
1.47 (0.76, 2.82)
hazard ratio (95% CI)
adjusted
10 2 3 4 5 6
adjusted hazard ratio
hazard ratios compared to no treatment
upper gastrointestinal bleed
citalopram (SSRI)
escitalopram (SSRI)
fluoxetine (SSRI)
paroxetine (SSRI)
sertraline (SSRI)
amitriptyline (TCA)
dosulepin (TCA)
lofepramine (TCA)
trazodone (TCA)
mirtazapine (Other)
venlafaxine (Other)
all others
Antidepressant
1.08 (0.96, 1.21)
1.35 (1.04, 1.75)
0.93 (0.83, 1.05)
1.13 (0.89, 1.43)
0.89 (0.71, 1.12)
1.14 (0.89, 1.45)
0.75 (0.51, 1.11)
0.99 (0.60, 1.63)
0.80 (0.39, 1.66)
1.29 (1.00, 1.68)
0.94 (0.73, 1.22)
1.00 (0.62, 1.63)
hazard ratio (95% CI)
adjusted
10 .5 1.5 2
adjusted hazard ratio
hazard ratios compared to no treatment
road traffic accident
citalopram (SSRI)
escitalopram (SSRI)
fluoxetine (SSRI)
paroxetine (SSRI)
sertraline (SSRI)
amitriptyline (TCA)
dosulepin (TCA)
lofepramine (TCA)
trazodone (TCA)
mirtazapine (Other)
venlafaxine (Other)
all others
Antidepressant
1.73 (1.42, 2.11)
1.59 (1.05, 2.42)
1.59 (1.28, 1.98)
2.13 (1.46, 3.12)
2.20 (1.60, 3.01)
2.99 (2.23, 4.02)
2.01 (1.33, 3.05)
4.16 (2.68, 6.44)
0.85 (0.21, 3.43)
2.47 (1.53, 3.98)
3.03 (2.08, 4.43)
2.95 (1.80, 4.85)
hazard ratio (95% CI)
adjusted
10 2 3 4 5 6 7
adjusted hazard ratio
hazard ratios compared to no treatment
adverse drug reaction
citalopram (SSRI)
escitalopram (SSRI)
fluoxetine (SSRI)
paroxetine (SSRI)
sertraline (SSRI)
amitriptyline (TCA)
dosulepin (TCA)
lofepramine (TCA)
trazodone (TCA)
mirtazapine (Other)
venlafaxine (Other)
all others
Antidepressant
1.32 (1.18, 1.48)
1.29 (0.99, 1.68)
1.38 (1.21, 1.56)
1.24 (0.97, 1.60)
1.59 (1.29, 1.96)
2.33 (1.99, 2.73)
1.36 (1.04, 1.77)
1.56 (1.05, 2.31)
1.97 (1.26, 3.08)
2.20 (1.76, 2.75)
1.40 (1.11, 1.77)
2.35 (1.76, 3.13)
hazard ratio (95% CI)
adjusted
10 2 3 4
adjusted hazard ratio
hazard ratios compared to no treatment
all-cause mortality
Fig. 2 Adjusted hazard ratios for falls, fracture, upper gastrointestinal bleed, road traffic accident, adverse drug reaction, and all-cause mortality for
individual antidepressant drugs over 5 years follow-up. TCA tricyclic and related antidepressant, SSRI selective serotonin reuptake inhibitor
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Table 5 Unadjusted and adjusted hazard ratios for six adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic accident,
adverse drug reaction, and all-cause mortality) by individual antidepressant drug compared with citalopram, over 5 years follow-up
Unadjusted analysis Adjusted analysisb
Antidepressant drug No of eventsa Person yearsa Hazard ratio 95% CI Hazard ratio 95% CI P
Falls
SSRIs:
Citalopram 628 92,765 1.00 1.00
Escitalopram 92 13,180 1.04 (0.84–1.28) 1.01 (0.82–1.25) 0.91
Fluoxetine 539 80,665 1.02 (0.91–1.15) 0.99 (0.88–1.12) 0.92
Paroxetine 115 16,322 1.06 (0.87–1.30) 1.05 (0.85–1.29) 0.65
Sertraline 117 18,619 0.91 (0.74–1.13) 0.92 (0.74–1.15) 0.47
TCAs:
Amitriptyline 161 18,929 1.27 (1.07–1.50) 0.98 (0.83–1.16) 0.84
Dosulepin 84 11,940 1.07 (0.83–1.37) 0.91 (0.70–1.17) 0.45
Lofepramine 27 4709 0.87 (0.59–1.29) 0.79 (0.53–1.18) 0.25
Trazodone 18 2335 1.22 (0.74–2.00) 0.98 (0.57–1.67) 0.94
Others:
Mirtazapine 72 9959 1.12 (0.90–1.40) 0.97 (0.77–1.22) 0.78
Venlafaxine 97 15,489 0.91 (0.74–1.12) 0.92 (0.75–1.13) 0.44
All other antidepressants 31 4839 0.94 (0.67–1.32) 0.83 (0.59–1.18) 0.30
Combined antidepressants 37 4121 1.26 (0.91–1.74) 1.08 (0.78–1.50) 0.65
No current use 2493 558,933 0.62 (0.57–0.68) 0.67 (0.61–0.73) < 0.001
Comparison between drugsc 0.98
Fracture
SSRIs:
Citalopram 645 85,297 1.00 1.00
Escitalopram 90 12,193 0.95 (0.77–1.18) 0.97 (0.78–1.21) 0.82
Fluoxetine 509 74,542 0.90 (0.80–1.01) 0.92 (0.82–1.04) 0.19
Paroxetine 99 15,167 0.85 (0.69–1.05) 0.86 (0.70–1.07) 0.19
Sertraline 121 17,149 0.94 (0.78–1.14) 0.95 (0.78–1.15) 0.59
TCAs:
Amitriptyline 98 17,646 0.73 (0.60–0.90) 0.68 (0.55–0.83) < 0.001
Dosulepin 59 11,075 0.70 (0.53–0.91) 0.67 (0.51–0.87) 0.003
Lofepramine 28 4309 0.88 (0.62–1.25) 0.84 (0.58–1.20) 0.33
Trazodone 15 2102 0.96 (0.59–1.57) 0.82 (0.50–1.35) 0.43
Others:
Mirtazapine 73 8938 1.04 (0.81–1.32) 0.93 (0.73–1.19) 0.56
Venlafaxine 106 14,174 0.96 (0.78–1.19) 0.96 (0.77–1.19) 0.68
All other antidepressants 23 4472 0.71 (0.49–1.03) 0.63 (0.43–0.93) 0.020
Combined antidepressants 29 3759 0.97 (0.65–1.45) 0.90 (0.60–1.35) 0.61
No current use 2759 510,172 0.70 (0.64–0.76) 0.74 (0.67–0.81) < 0.001
Comparison between drugsc 0.015
Upper GI bleed
SSRIs:
Citalopram 110 94,862 1.00 1.00
Escitalopram 20 13,436 1.24 (0.76–2.03) 1.29 (0.78–2.12) 0.32
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Table 5 Unadjusted and adjusted hazard ratios for six adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic accident,
adverse drug reaction, and all-cause mortality) by individual antidepressant drug compared with citalopram, over 5 years follow-up
(Continued)
Unadjusted analysis Adjusted analysisb
Antidepressant drug No of eventsa Person yearsa Hazard ratio 95% CI Hazard ratio 95% CI P
Fluoxetine 123 82,236 1.28 (0.99–1.66) 1.24 (0.95–1.62) 0.11
Paroxetine 26 16,569 1.28 (0.83–1.98) 1.17 (0.75–1.82) 0.49
Sertraline 18 18,964 0.84 (0.52–1.35) 0.79 (0.48–1.30) 0.35
TCAs:
Amitriptyline 35 19,565 1.60 (1.11–2.30) 1.29 (0.88–1.89) 0.19
Dosulepin 22 12,178 1.63 (1.07–2.48) 1.31 (0.85–2.02) 0.22
Lofepramine 7 4817 1.18 (0.51–2.71) 1.03 (0.45–2.36) 0.95
Trazodone 10 2343 3.94 (2.13–7.26) 2.73 (1.44–5.17) 0.002
Others:
Mirtazapine 19 10,154 1.75 (1.10–2.79) 1.19 (0.73–1.95) 0.48
Venlafaxine 30 15,664 1.76 (1.19–2.58) 1.53 (1.03–2.27) 0.034
All other antidepressants 9 4945 1.71 (0.90–3.25) 1.41 (0.72–2.78) 0.31
Combined antidepressants 12 4245 2.49 (1.37–4.53) 2.04 (1.12–3.74) 0.020
No current use 588 570,654 0.94 (0.76–1.16) 0.96 (0.78–1.19) 0.73
Comparison between drugsc 0.08
Road traffic accident
SSRIs:
Citalopram 398 91,139 1.00 1.00
Escitalopram 71 12,981 1.25 (0.96–1.64) 1.25 (0.95–1.64) 0.11
Fluoxetine 311 79,365 0.91 (0.78–1.05) 0.86 (0.74–1.01) 0.06
Paroxetine 78 16,030 1.11 (0.86–1.43) 1.05 (0.81–1.35) 0.73
Sertraline 69 18,362 0.87 (0.69–1.10) 0.82 (0.64–1.06) 0.13
TCAs:
Amitriptyline 85 18,784 1.04 (0.80–1.36) 1.05 (0.80–1.38) 0.72
Dosulepin 35 11,855 0.68 (0.46–1.00) 0.70 (0.47–1.04) 0.08
Lofepramine 20 4694 0.93 (0.56–1.56) 0.92 (0.55–1.52) 0.74
Trazodone 7 2294 0.68 (0.33–1.41) 0.74 (0.35–1.55) 0.43
Others:
Mirtazapine 50 9826 1.16 (0.88–1.52) 1.20 (0.91–1.58) 0.20
Venlafaxine 60 15,179 0.94 (0.72–1.22) 0.87 (0.67–1.14) 0.31
All other antidepressants 19 4777 0.90 (0.55–1.46) 0.93 (0.57–1.52) 0.77
Combined antidepressants 18 4063 1.01 (0.64–1.59) 1.04 (0.66–1.65) 0.87
No current use 2343 546,915 1.01 (0.90–1.13) 0.93 (0.82–1.04) 0.19
Comparison between drugsc 0.045
Adverse drug reaction
SSRIs:
Citalopram 163 94,933 1.00 1.00
Escitalopram 21 13,436 0.95 (0.61–1.48) 0.92 (0.58–1.45) 0.72
Fluoxetine 134 82,362 0.95 (0.75–1.21) 0.92 (0.72–1.17) 0.51
Paroxetine 36 16,608 1.20 (0.82–1.76) 1.23 (0.83–1.82) 0.29
Sertraline 40 18,967 1.24 (0.91–1.70) 1.27 (0.92–1.74) 0.14
TCAs:
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the aHRs for the other drug classes were similar in both
analyses (Table 6). HRs for the individual drugs when com-
pared with citalopram were similar in the 1- and 5-year ana-
lyses, except for venlafaxine, where the aHR was higher in
the analysis restricted to the first year of follow-up than in
the 5-year analysis (aHR 3.10, 95% CI 1.88–5.11) (Additional
file 1: Table S3), and there were significant differences
between the 11 most commonly prescribed antidepressants
(P = 0.002).
Results of analyses for road traffic accidents
There were no significant associations between road
traffic accidents and the antidepressant drug classes
Table 5 Unadjusted and adjusted hazard ratios for six adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic accident,
adverse drug reaction, and all-cause mortality) by individual antidepressant drug compared with citalopram, over 5 years follow-up
(Continued)
Unadjusted analysis Adjusted analysisb
Antidepressant drug No of eventsa Person yearsa Hazard ratio 95% CI Hazard ratio 95% CI P
Amitriptyline 66 19,635 1.94 (1.45–2.60) 1.73 (1.27–2.34) < 0.001
Dosulepin 27 12,162 1.23 (0.80–1.88) 1.16 (0.75–1.81) 0.50
Lofepramine 21 4819 2.39 (1.55–3.70) 2.40 (1.56–3.70) < 0.001
Trazodone < 5 2372 0.50 (0.12–2.00) 0.49 (0.12–1.99) 0.32
Others:
Mirtazapine 23 10,224 1.48 (0.92–2.37) 1.42 (0.88–2.31) 0.15
Venlafaxine 40 15,689 1.72 (1.16–2.55) 1.75 (1.17–2.62) 0.006
All other antidepressants 15 4949 1.81 (1.11–2.98) 1.71 (1.03–2.83) 0.038
Combined antidepressants 11 4257 1.78 (0.98–3.24) 1.69 (0.92–3.09) 0.09
No current use 432 571,401 0.54 (0.45–0.65) 0.58 (0.47–0.70) < 0.001
Comparison between drugsc < 0.001
All-cause mortality
SSRIs:
Citalopram 405 95,640 1.00 1.00
Escitalopram 57 13,539 0.99 (0.77–1.26) 0.98 (0.75–1.27) 0.87
Fluoxetine 347 82,935 1.00 (0.88–1.15) 1.04 (0.91–1.20) 0.56
Paroxetine 64 16,705 0.93 (0.72–1.19) 0.94 (0.73–1.21) 0.64
Sertraline 97 19,139 1.18 (0.96–1.46) 1.21 (0.97–1.50) 0.09
TCAs:
Amitriptyline 194 19,845 2.28 (1.93–2.69) 1.77 (1.49–2.10) < 0.001
Dosulepin 64 12,292 1.23 (0.95–1.60) 1.03 (0.78–1.35) 0.83
Lofepramine 29 4863 1.42 (0.98–2.05) 1.18 (0.79–1.76) 0.42
Trazodone 24 2390 2.30 (1.47–3.60) 1.49 (0.95–2.35) 0.08
Others:
Mirtazapine 110 10,343 2.54 (2.07–3.11) 1.67 (1.33–2.09) < 0.001
Venlafaxine 73 15,835 1.11 (0.88–1.42) 1.06 (0.83–1.36) 0.65
All other antidepressants 48 5001 2.25 (1.68–3.02) 1.78 (1.32–2.38) < 0.001
Combined antidepressants 41 4299 2.29 (1.68–3.12) 1.67 (1.21–2.31) 0.002
No current use 1541 575,623 0.63 (0.57–0.71) 0.76 (0.68–0.85) < 0.001
Comparison between drugsc < 0.001
aBased on numbers in adjusted analysis
bAdjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group (white/not recorded or
non-white), coronary heart disease, diabetes, hypertension, cancer, epilepsy/seizures, hypothyroidism, osteoarthritis, asthma/chronic obstructive airways disease,
stroke/TIA, rheumatoid arthritis, osteoporosis, liver disease, renal disease, obsessive-compulsive disorder, statins, NSAIDS, aspirin, antihypertensive drugs, anticonvulsants,
hypnotics/anxiolytics, oral contraceptives, hormone replacement therapy, antipsychotics, bisphosphonates, anticoagulants; fracture outcome also adjusted for falls
cComparison is between the 11 individual drugs
GI gastrointestinal, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic and related antidepressants
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Table 6 Unadjusted and adjusted hazard ratios for six adverse outcomes (falls, fracture, upper gastrointestinal bleed, road traffic
accident, adverse drug reaction, and all-cause mortality) by antidepressant class compared with no antidepressant treatment, over 1
year follow-up
Unadjusted analysis Adjusted analysisb
Antidepressant class No of eventsa Person-yearsa Hazard ratio 95% CI Hazard ratio 95% CI P
Falls
No current use 421 93,760 1.00 1.00
TCAs 87 16,178 1.33 (1.06–1.68) 1.05 (0.83–1.33) 0.69
SSRIs 547 98,916 1.29 (1.12–1.48) 1.26 (1.10–1.45) 0.001
Other antidepressants 44 8220 1.29 (0.96–1.74) 1.15 (0.84–1.57) 0.39
Combined antidepressants 6 848 1.82 (0.88–3.76) 1.40 (0.64–3.06) 0.40
Comparison between groupsc 0.42
Fracture
No current use 484 85,735 1.00 1.00
TCAs 74 14,901 0.92 (0.72–1.17) 0.81 (0.63–1.05) 0.11
SSRIs 609 90,901 1.20 (1.06–1.37) 1.16 (1.02–1.33) 0.021
Other antidepressants 62 7437 1.46 (1.12–1.90) 1.29 (0.99–1.68) 0.06
Combined antidepressants 6 779 1.33 (0.60–2.95) 1.17 (0.53–2.59) 0.70
Comparison between groupsc 0.030
Upper GI bleed
No current use 108 95,101 1.00 1.00
TCAs 34 16,409 1.74 (1.21–2.49) 1.53 (1.05–2.23) 0.025
SSRIs 146 100,228 1.16 (0.91–1.50) 1.26 (0.97–1.63) 0.08
Other antidepressants 28 8282 2.92 (1.93–4.43) 2.42 (1.56–3.76) < 0.001
Combined antidepressants < 5 861 2.85 (0.91–8.90) 2.42 (0.80–7.28) 0.12
Comparison between groupsc 0.006
Road traffic accident
No current use 415 91,721 1.00 1.00
TCAs 52 15,911 0.73 (0.52–1.02) 0.82 (0.58–1.14) 0.24
SSRIs 442 96,813 1.03 (0.91–1.18) 1.07 (0.93–1.23) 0.35
Other antidepressants 39 8037 1.11 (0.79–1.56) 1.16 (0.82–1.62) 0.41
Combined antidepressants < 5 832 0.77 (0.25–2.36) 0.84 (0.27–2.60) 0.76
Comparison between groupsc 0.35
Adverse drug reaction
No current use 91 95,252 1.00 1.00
TCAs 62 16,444 2.99 (2.15–4.17) 2.73 (1.95–3.83) < 0.001
SSRIs 228 100,326 1.92 (1.49–2.45) 1.82 (1.41–2.34) < 0.001
Other antidepressants 29 8316 3.35 (2.13–5.28) 3.16 (1.99–5.03) < 0.001
Combined antidepressants < 5 861 4.67 (1.70–12.85) 4.59 (1.66–12.71) 0.003
Comparison between groupsc 0.005
All-cause mortality
No current use 298 95,801 1.00 1.00
TCAs 88 16,560 1.58 (1.23–2.04) 1.12 (0.86–1.46) 0.39
SSRIs 408 100,907 1.22 (1.05–1.41) 1.09 (0.93–1.27) 0.29
Other antidepressants 56 8380 2.01 (1.53–2.65) 1.39 (1.04–1.85) 0.024
Combined antidepressants 8 868 2.77 (1.37–5.59) 1.81 (0.86–3.81) 0.12
Comparison between groupsc 0.22
aBased on numbers in adjusted analysis
bAdjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group (white/not recorded or non-white),
coronary heart disease, diabetes, hypertension, cancer, epilepsy/seizures, hypothyroidism, osteoarthritis, asthma/chronic obstructive airways disease, stroke/TIA, rheumatoid
arthritis, osteoporosis, liver disease, renal disease, obsessive-compulsive disorder, statins, NSAIDS, aspirin, antihypertensive drugs, anticonvulsants, hypnotics/anxiolytics, oral
contraceptives, hormone replacement therapy, antipsychotics, bisphosphonates, anticoagulants; fracture outcome also adjusted for falls
cComparison between the four different drug groups including combined antidepressants but not no current use
GI gastrointestinal, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic and related antidepressants
Coupland et al. BMC Medicine  (2018) 16:36 Page 16 of 24
(Table 2) or individual drugs (Fig. 2 and Table 5), and no
significant trends with dose (Table 4).
Results of analyses for adverse drug reactions
Rates of adverse drug reactions over 5 years of follow-up
were significantly increased for all classes of antidepres-
sants compared with non-use (Table 2). There were sig-
nificant differences between the classes overall, with
higher rates for tricyclic and related antidepressants and
other antidepressants when directly compared with
selective serotonin reuptake inhibitors (aHRs 1.54 (95%
CI 1.25–1.88) and 1.61 (1.22–2.12), respectively; Table 3),
but no significant trends with dose in any of the drug
classes (Table 4).
Most of the 11 most commonly prescribed antidepres-
sants were associated with significantly increased risks
(at P < 0.01) compared with non-use over 5 years of follow-
up (Fig. 2), with the exception of trazodone (P = 0.82) and
escitalopram (P = 0.03). There were significant overall
differences between the most commonly prescribed antide-
pressants with significantly higher rates for amitriptyline,
lofepramine and venlafaxine when compared with citalo-
pram as the reference category (Table 5).
There was a significant interaction between antidepres-
sant drug class and age (P < 0.001) with higher aHRs in
people aged 20–44 than those aged 45–64 years for all
drug classes when compared with untreated periods over
5 years of follow-up (Additional file 1: Table S2).
Results of analyses for all-cause mortality
In the analysis of 5 years of follow-up, all-cause mortality
rates were significantly increased for all classes of antide-
pressants compared with non-use (Table 2). The reductions
in HRs comparing unadjusted and adjusted results were
mainly due to adjustment for age, with some additional
decreases from adjusting for use of other drugs. When
directly compared with selective serotonin reuptake inhib-
itors, mortality rates were significantly higher for tricyclic
and related antidepressants, other antidepressants and
combined antidepressants (aHRs 1.39 (95% CI 1.22–1.59),
1.26 (1.08–1.47) and 1.58 (1.16–2.17), respectively; Table 3)
with significant differences between the drug classes.
There were no significant trends with dose in any of the
drug classes (Table 4).
HRs for the 11 most commonly prescribed antidepres-
sants compared with non-use are shown in Fig. 2. In the
analysis with citalopram as the reference group, there
were significantly higher mortality rates for amitriptyline
(aHR 1.77, 95% CI 1.49–2.10) and mirtazapine (aHR
1.67, 95% CI 1.33–2.09; Table 5), with significant differ-
ences between the 11 most commonly prescribed antide-
pressants overall (P < 0.001).
In the analysis restricted to the first year of follow-up,
there were no significant increases in mortality rates for
any of the drug classes compared with non-use (at P < 0.01;
Table 6), and HRs for tricyclic and related antidepressants,
other antidepressants and combined antidepressants
were no longer significantly increased when compared
with selective serotonin reuptake inhibitors (aHRs
1.03 (95% CI 0.80–1.32), 1.28 (0.97–1.68) and 1.67
(0.80–3.49), respectively).
For individual drugs during the first year of follow-up
the HR for amitriptyline was lower than in the 5-year
analysis and was not associated with a significantly
increased mortality rate compared with citalopram (1.36,
95% CI 0.99–1.86), but the HR for mirtazapine was
almost the same as in the 5-year analysis (aHR 1.63, 95%
CI 1.12–2.38, P = 0.011; Additional file 1: Table S3),
although numbers were smaller.
Analyses of duration of use
HRs according to time since starting and stopping treat-
ment for each antidepressant class over 5 years of
follow-up are shown in Additional file 1: Table S4. These
show that, generally, rates remained increased through-
out treatment for all classes of antidepressants for falls.
For fractures, the rates were significantly increased after
28 days of starting selective serotonin reuptake inhibitor
treatment and during the 28–84 days after starting treat-
ment with the group of other antidepressants. For
adverse drug reactions, rates were highest during the
first 28 days of treatment but remained increased
throughout treatment for all antidepressant classes.
All-cause mortality rates were only significantly in-
creased during the first 28 days of treatment for all
antidepressant classes, and were significantly reduced after
treatment of 85 or more days with selective serotonin
reuptake inhibitors. All-cause mortality rates were highest
during the first 1–28 days after stopping treatment.
Sensitivity analyses
There were some differences between the results of ana-
lyses restricted to 1 year of follow-up and the main 5-year
analyses as described above. When the entire follow-
up period was used, and when patients who had not
received any antidepressant prescriptions during
follow-up were removed from the analysis, the aHRs
comparing antidepressant classes with untreated
periods were similar to those in the main 5-year analyses
for all outcomes (Additional file 1: Table S5).
Absolute risks
Table 7 shows absolute risks of the six outcomes over 1
year by antidepressant class and for the individual drugs.
Absolute risks were mostly less than 60 per 10,000 pa-
tients over 1 year and were highest overall for falls and
fractures. The absolute risk of fracture associated with
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selective serotonin reuptake inhibitors was 20 per 10,000
higher than for tricyclic and related antidepressants, and
for other antidepressants it was 27 per 10,000 higher.
The absolute risk of a gastrointestinal bleed was 29 per
10,000 higher for venlafaxine compared with citalopram.
Mirtazapine was associated with an excess risk of 23 per
10,000 for all-cause mortality compared with citalopram.
Discussion
This large study found several differences in the rates of
adverse outcomes between different antidepressant clas-
ses and individual drugs in people aged 20–64 years with
a diagnosis of depression. Our key findings were that
selective serotonin reuptake inhibitors and other antide-
pressants were associated with significantly increased
fracture rates. All drug classes were associated with sig-
nificantly increased risks of falls. Rates of adverse drug
reaction were significantly higher for tricyclic and related
antidepressants and other antidepressants than for
selective serotonin reuptake inhibitors. Mortality rates
were significantly higher for tricyclic antidepressants and
other antidepressants than with selective serotonin
reuptake inhibitor treatment over 5 years of follow-up,
but not during the first year of follow-up.
Among individual antidepressant drugs, fracture rates
were significantly increased for citalopram, escitalopram, flu-
oxetine, sertraline and venlafaxine compared with periods of
non-use of antidepressants. Amitriptyline, lofepramine and
venlafaxine were associated with significantly higher rates of
adverse drug reactions compared with citalopram. Trazo-
done was associated with a significantly higher rate of upper
gastrointestinal bleeding over 5 years of follow-up. Mirtaza-
pine and amitriptyline were associated with highest mortal-
ity rates over 5 years of follow-up, but only mirtazapine was
associated with a significantly increased risk during the first
year of follow-up.
In this cohort of adults aged 20–64 years, the absolute
risks of the adverse outcomes were mostly less than 0.6%
per year, and for falls, fractures, upper gastrointestinal
bleeding and all-cause mortality they were considerably
Table 7 Absolute risks of falls, fracture, upper gastrointestinal bleed, road traffic accident, adverse drug reaction, and all-cause mortality
over 1 year by antidepressant class and for individual antidepressant drugs
Absolute risks (per 10,000 persons) over 1 yeara,b
Falls Fracture Upper GI bleed Road traffic accident Adverse drug reaction All-cause mortality
Antidepressant class
SSRIs 57 66 15 49 18 36
TCAs 47 46 18 38 27 37
Other antidepressants 52 73 29 53 32 46
Combined antidepressants 63 67 29 39 46 60
Antidepressant drug
SSRIs:
Citalopram 56 66 13 50 16 36
Escitalopram 66 65 19 62 21 38
Fluoxetine 57 66 17 43 16 35
Paroxetine 60 71 17 61 26 29
Sertraline 52 66 5 55 28 38
TCAs:
Amitriptyline 59 48 19 41 25 49
Dosulepin 45 52 15 29 22 22
Lofepramine 30 38 16 39 56 45
Trazodone 33 34 38 43 c 23
Others:
Mirtazapine 62 60 19 56 27 59
Venlafaxine 43 81 42 47 38 34
All other antidepressants 29 70 23 72 32 52
No treatment 45 57 12 46 10 33
aAbsolute risks are adjusted for confounders listed in Table 2
bAbsolute risks over 1 year evaluated using adjusted hazard ratios from analyses restricted to 1 year of follow-up
cInsufficient numbers for calculation
SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic and related antidepressants
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lower than the equivalent risks in older people [26]. Whilst
for individuals the excess risks associated with antidepres-
sant use are low, given the widespread use of these drugs in
adults, the population effects could be considerable.
Additional analyses examining patterns of risk accord-
ing to duration of use found the increases in all-cause
mortality rates across all antidepressant classes were
only apparent during the first 28 days of treatment, after
which they declined rapidly. This is a period during
which depressive symptoms can be most severe, and we
have previously shown that rates of suicide and self-
harm in this cohort were highest in the first 28 days
after starting antidepressant treatment [22]. Mortality
rates were also substantially increased in the first 28 days
after stopping antidepressants, which may reflect
patients stopping medication due to onset of illness or
hospital or hospice admission rather than a direct effect
of drug withdrawal. Although amitriptyline was associ-
ated with the highest increase in mortality rates over 5
years of follow-up it was not associated with a signifi-
cantly increased risk during the first year of follow-up.
The increased risk over 5 years of follow-up might occur
due to amitriptyline being initiated to relieve neuro-
pathic pain in patients who developed cancer although it
is not specifically licenced for this in the UK [33]. How-
ever, the increased mortality rate for mirtazapine was
similar in magnitude in the 1- and 5-year analyses.
Strengths and limitations
This study included a large representative sample of
238,963 people aged 20–64 diagnosed with depression in
the general UK population. All eligible patients were
included, so there is no selection bias arising from non-
response. Data on prescriptions and confounding vari-
ables were recorded prospectively before the outcomes
occurred, thereby avoiding recall bias.
To reduce indication bias we only included patients
with a diagnosis of depression, since antidepressants,
and particularly tricyclic antidepressants, are prescribed
for a range of indications, including off-label conditions
such as insomnia and pain, and these indications will be
associated with the outcomes considered in this study to
a varying degree [34]. Depression itself is an established
risk factor for several of the outcomes considered here,
including falls, fracture and all-cause mortality [35–39],
and restricting the cohort to patients with a diagnosis of
depression helped distinguish the effects of antidepres-
sant treatment from those of depression itself. We also
adjusted for severity of depression at first diagnosis,
although we were not able to account for changes in
severity of depression over time as depression severity
scores are not routinely recorded in general practice.
Our cohort only included people with a first diagnosis of
depression who had not previously been prescribed
antidepressants to avoid biases associated with prevalent
use or prior experiences during previous treatment epi-
sodes [40]. The results of the sensitivity analyses exclud-
ing patients who did not receive antidepressant
prescriptions during follow-up were very similar to the
main analyses where these patients contributed follow-
up time to the unexposed reference category. This indi-
cates that including these patients who may differ in
terms of treatment preferences and other personal char-
acteristics did not distort the results.
We carried out analyses directly comparing event rates
during treatment with different antidepressant classes as
well as including comparisons with untreated periods.
Comparisons with untreated periods of time are still sus-
ceptible to indication bias since the depression may have
resolved or be less severe during these periods, leading
to a reduced incidence of the events. Further, this could
explain the increased rates of mortality during periods of
treatment with all classes of antidepressant compared
with untreated periods, particularly in the 5-year ana-
lysis, where patients receiving antidepressant treatment
after 1 year are likely to have more severe or treatment-
resistant depression. The analyses directly comparing
treated groups with each other are less vulnerable to
these biases.
We accounted for a large number of potential
confounding variables in the analysis, including other
comorbidities and use of other medications; however, as
with any observational study, the findings are still
susceptible to residual confounding due to lack of
adjustment for certain potential risk factors such as
dietary factors and physical activity, which are not rou-
tinely recorded in primary care. Similarly, we did not ad-
just for chronic pain, since it is inconsistently recorded
in primary care, or for conditions such as multiple scler-
osis and fibromyalgia, but these would likely have a low
prevalence in this age group.
Our outcomes were restricted to medical outcomes
recorded in GP records or on death certificates, and we
were not able to include pertinent outcomes such as
interpersonal and psychological effects as they are sel-
dom included in these records [41]. A further limitation
is that the outcomes were not formally adjudicated in
this study, and some more minor events, such as might
occur for falls, adverse drug reactions or road traffic ac-
cidents, would not be medically reported or recorded so
there will be some misclassification of the outcomes; this
also means our findings for these outcomes relate to
more severe, medically reported events. Validation stud-
ies in other UK primary care databases have shown high
levels of validity across a range of diseases; for example,
Khan [42] reported high positive predictive values for
validation studies of upper gastrointestinal bleeding and
hip fracture. We included information from death
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certificates to identify additional patients with the out-
comes, which will have increased ascertainment and re-
duced misclassification. However, most codes used to
identify road traffic accidents did not indicate whether
the person was driving or a passenger, or whether they
were responsible for the crash; therefore, findings for
this outcome are particularly susceptible to misclassifica-
tion biases. We excluded patients with a prior history of
each adverse outcome from the analysis of that outcome
to ensure that only new events were included and to re-
move potential biases arising from changes to treatments
and behaviours as a consequence of prior events.
There is likely to be some misclassification of the anti-
depressant exposure variables as patients may not have
actually taken their prescribed antidepressant medica-
tion, or may not have taken it at the prescribed dose.
This misclassification could underestimate associations
with drug use. Furthermore, although the cohort was
large, the number of events was small for some of the
antidepressant exposure categories and some of the
stratified analyses.
Comparison with other studies
Many observational studies have consistently found
increased risks of falls in older people taking antidepres-
sants [26, 43–45]. Fewer studies have examined the risks
in younger people. Our findings show that rates of falls
are also increased in younger people taking antidepres-
sants, and increase with dose. A review of studies in
older people found that the increased risks of falls were
similar for selective serotonin reuptake inhibitors and tri-
cyclic antidepressants [14]; likewise, we found associations
were similar for these drug classes in younger people. A
number of factors are likely to explain the increased risk
of falls associated with antidepressants, including effects
on concentration, balance and reaction times, and ortho-
static hypertension and sedative effects, particularly for
the tricyclic antidepressants and mirtazapine, and sleep
disturbance with selective serotonin reuptake inhibitors
resulting in drowsiness and dizziness [14].
Our finding of an increased risk of fracture for select-
ive serotonin reuptake inhibitors concurs with the find-
ings of many other observational studies [15, 46],
though these have predominantly been conducted in
older populations, whilst we found an increased risk
even in people aged 20–44. These increases may be due
to decreased bone density since use of selective sero-
tonin reuptake inhibitors has been shown to be associ-
ated with a reduction in bone mineral density and bone
loss, even in adolescent boys [47]. We did not find an
increased fracture risk for tricyclic antidepressants,
which contrasts with the findings of two systematic re-
views [15, 48], although these found smaller increases
for tricyclic antidepressants than for selective serotonin
reuptake inhibitors [46]. A Danish case-control study
[49] that examined age and dose effects for selective
serotonin reuptake inhibitors and tricyclic antidepres-
sants found that the fracture risk associated with select-
ive serotonin reuptake inhibitors increased with age but
only in medium- and high-dose users, whilst for tricyc-
lic antidepressants there was only an increased fracture
risk in the oldest age group (> 60 years) for the highest
dose. Few studies have examined other antidepressants
or individual antidepressants, yet a recent cohort study
of middle-aged and older adults found similar fracture
risks when comparing serotonin-norepinephrine re-
uptake inhibitors (venlafaxine and duloxetine) with se-
lective serotonin reuptake inhibitors [50].
Several studies have found upper gastrointestinal bleed-
ing to be more common among patients taking selective
serotonin reuptake inhibitors, particularly when used in
combination with non-steroidal anti-inflammatory drugs
[17, 51]. A number of mechanisms have been proposed
for this increased risk, including depletion of platelet sero-
tonin content causing an inhibition of platelet plug forma-
tion or direct toxicity on the gastrointestinal mucosa [52].
In our study, we found a higher risk for tricyclic and re-
lated antidepressants than for selective serotonin reuptake
inhibitors, although this was only in the lowest dose
category and may therefore reflect preferential prescribing
of low-dose tricyclic antidepressants rather than selective
serotonin reuptake inhibitors in people with suspected
risk factors for bleeding. We did not find a stronger asso-
ciation when selective serotonin reuptake inhibitors were
used in combination with non-steroidal anti-inflammatory
drugs, although, as our study was in a younger age group
than most previous studies, these differences may be due
to smaller numbers prescribed this drug combination.
Our finding that venlafaxine and trazodone were associ-
ated with the highest risks has been found in other studies
[26, 53–55].
Increased tolerability of selective serotonin reuptake
inhibitors in comparison with tricyclic antidepressants is
long established [56–58], with selective serotonin
reuptake inhibitors having fewer side effects and adverse
reactions, particularly for anticholinergic and sedating
effects. Lofepramine had the highest rate of adverse drug
reactions in this study, as we also found in our study of
older people [26], though this drug was prescribed at
higher doses than the other antidepressants. Venlafaxine
was also associated with an increased risk of adverse
drug reactions compared with citalopram, which concurs
with the findings of a meta-analysis of double-blind ran-
domized trials that reported higher rates of discontinu-
ation due to adverse events for venlafaxine compared
with selective serotonin reuptake inhibitors [59]. Ami-
triptyline was mainly prescribed at low doses, but still
showed an increased risk of adverse drug reactions.
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We found no evidence of associations with antidepres-
sant treatment for road traffic accidents, although our out-
come was broad and not specific to drivers of vehicles.
Findings from other studies are inconclusive, with some
showing increased risks for selective serotonin reuptake in-
hibitors and some for tricyclic antidepressants particularly
in older people, whilst others have shown no associations
with antidepressant use [16, 60–64]. Many of these studies
have not accounted for depression, which itself can impair
driving performance [65, 66].
Our findings of increased mortality rates over 5 years
for all antidepressant classes are similar to those of a co-
hort study in postmenopausal women that found in-
creased mortality rates among users of selective serotonin
reuptake inhibitors, tricyclic and related antidepressants,
and other antidepressants with a mean follow-up of 5.9
years [19]. The authors proposed possible mechanisms for
these associations but also suggested they could be due to
antidepressant use reflecting other causes of increased
mortality, such as residual depressive symptoms, that may
not have been fully controlled. Previous observational
studies in people aged 65 and over have found mirtazapine
to be associated with the highest increases in mortality
rates [26, 67]. A study of FDA Summary Basis of Approval
reports was carried out to assess whether medication may
worsen the already increased mortality risk for patients
with severe psychiatric illness [38]. This study combined
mortality rates across short- or medium-term randomised
clinical trials of psychotropic drugs in patients with psy-
chiatric illness, and found that, among patients with de-
pression, the overall mortality risk was similar for selective
serotonin reuptake inhibitors or selective serotonin-
norepinephrine reuptake inhibitors compared to placebo,
but there was a significantly higher risk for the group of
heterocyclic antidepressants, which included amitryptiline,
imipramine, maprotiline and mirtazapine. Suicide was the
most common cause of death. This study of trial data,
which is not susceptible to residual confounding, provides
some support for our findings of increased mortality rates
for amitryptiline and mirtazapine in comparison with cita-
lopram, although the study did not assess these drugs in-
dividually and the number of deaths was low. Herein, we
have not investigated specific causes of death, although in
an analysis of suicide we found a 3.7-fold increased risk
for mirtazapine but no association for amitryptiline [22],
although suicide only accounted for a relatively small pro-
portion of all deaths.
Clinical implications and future research
Antidepressants are one of the most commonly pre-
scribed medications in younger and middle-aged adults,
although their benefits in the treatment of depression
may be relatively small, especially for mild and moder-
ate depression [10, 68]. These small beneficial effects
could be outweighed by harmful effects, but there is
limited evidence on their safety in younger and middle-
aged adults, particularly for outcomes such as falls and
fracture. Although susceptible to indication bias and re-
sidual confounding, this study has found increased
rates of falls, fractures, upper gastrointestinal bleeds,
adverse drug reactions and all-cause mortality during
periods of antidepressant use compared with non-
use for most classes of antidepressant. This study also
found that, over 5 years, selective serotonin reuptake
inhibitors and other antidepressants were associated
with significantly increased fracture rates compared
with tricyclic and related antidepressants, whereas rates
of all-cause mortality and adverse drug reaction were
significantly higher for tricyclic and related antidepres-
sants and other antidepressants than for selective sero-
tonin reuptake inhibitors. These risks should be
carefully considered and balanced against potential
benefits for individual patients when the decision to
prescribe an antidepressant is made so as to avoid un-
necessary treatment or to help select the most appro-
priate treatment where required.
Of particular concern is the association of mirtazapine
with increased suicide and mortality rates in each of the
observational studies that we have performed [22, 26]
and in the US study of randomised controlled trial re-
ports [38], whereas other antidepressant drugs have
shown inconsistent relationships with mortality risk.
This relationship, along with the increased risk for ami-
triptyline over 5 years, requires further investigation to
ascertain how much of the increased risk for mortality is
associated with suicide and other specific causes of
death, how much due to selective prescribing in people
with life threatening illness (such as because of the sed-
ation it produces to aid sleep in people who might have
pain as well as depression) and how much is due to
some other mechanism.
Conclusions
This large study of potential adverse outcomes in com-
bination with the findings for cardiovascular outcomes
[24], suicide and self-harm [22], and epilepsy [23] has
provided a comprehensive assessment of antidepressant
safety in people aged 20–64 years diagnosed with de-
pression. Although the findings are from an observa-
tional study design and are therefore susceptible to
residual confounding, our results do indicate potential
increased risks for some adverse outcomes for consid-
eration when antidepressants are prescribed. Thus,
even though they are quite rare outcomes, these ad-
verse effects of antidepressants need to be considered
alongside the benefits in working age adults as well as
in older people.
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